Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 119Breast 11Tumor-Agnostic 4Thoracic 3Gynecologic 3Head & Neck 2Gastrointestinal 2Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Recurrent Endometrial Endometrioid Adenocarcinoma 1Ovarian Neoplasms 1Advanced Epithelial Ovarian 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 134pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Letrozole 28Drug Therapy 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23durvalumab 22Albumin-Bound Paclitaxel 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20Specimen Handling 20Filgrastim 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × enzalutamide × Gynecologic × Clear all
NCT02684227 2025-03-19

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
50 enrolled 14 charts
Gynecologic

Recurrent Endometrial Endometrioid Adenocarcinoma

NCT01974765 2023-04-28

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
59 enrolled 11 charts
Gynecologic

Advanced Epithelial Ovarian

NCT03464201 2023-02-22

GREKO III

Grupo EspaƱol de Tumores HuƩrfanos e Infrecuentes

Phase 2 Completed
16 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔